DataMeds outlines peptide compounding plans after FDA policy proposal
The company is positioning for compounded peptide production as federal regulators weigh an interim access policy.
DO
By Daniel Okafor · Regulatory Correspondent
Oct 16 06:05 ETSource: StreetInsider
The wire
- 01DataMeds said it has plans to compound peptides following an FDA policy proposal covering access to certain peptide injections.
- 02Pharmacies and telehealth operators are staking out positions before federal enforcement posture on compounded peptides is settled.
- 03Details of the company's plans, product list and timing were not disclosed, and the underlying federal policy has not been finalized.
From the source
Read at streetinsider.comDataMeds outlines peptide compounding plans after FDA policy proposal
